Pentraxin 3 (PTX3) is a key pattern recognition receptor and a prominent member of the long pentraxin subfamily. Unlike short pentraxins such as C-reactive protein (CRP), PTX3 is synthesized locally by vascular endothelial cells, macrophages, and dendritic cells in response to inflammatory signals. PTX3 plays a dual role in human pathology: it acts as a critical node in vascular inflammation, cardiovascular diseases, and select infectious states, while also modulating FGF2-mediated angiogenesis and tumor microenvironments in oncology. Developing therapeutics targeting PTX3 requires robust reagents that preserve its complex octameric structure and native glycosylation patterns.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PTX3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human PTX3 Protein HEK293 expressed for native octameric glycosylation. High purity (>95%), Endotoxin controlled. Sequence Verified. |
View PTX3 Products |
| Gene Delivery | PTX3 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and expression validation. |
View PTX3 Products |
| Benchmark Ab | Anti-PTX3 Recombinant Antibody Recombinant positive control antibody for assay setup and validation. |
View PTX3 Products |
| Validator | PTX3 siRNA Set Target-specific siRNA pool for gene knockdown and functional specificity assays. |
View PTX3 Products |
| Related Target A | FGF2 (Fibroblast Growth Factor 2) PTX3 physically interacts with FGF2 to inhibit angiogenesis; essential for oncology screening. |
View FGF2 Products |
| Related Target B | C1q (Complement Component 1q) PTX3 binds C1q to regulate classical complement activation; key for immunology screening. |
View C1q Products |
| Related Target C | CRP (C-Reactive Protein) Short pentraxin used for selectivity and counter-screening panels. |
View CRP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Maintaining Covalent Octameric Conformation | HEK293 expression system preserves native disulfide-linked multimeric structure and Asn220 glycosylation. |
| Selectivity Against Short Pentraxins | CRP and SAP homolog panel proteins available for rigorous counter-screening assays. |
| Lack of Validated Reference Controls | Sequence-verified clinical benchmark antibodies available as positive controls. |
| Assay Interference from Endotoxins | Strict endotoxin control (<1.0 EU/μg) prevents non-specific TLR activation in cell-based assays. |
Live PTX3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development surrounding PTX3 is expanding beyond its classical role as a cardiovascular biomarker. Current drug discovery pipelines are actively targeting the PTX3 axis in chronic inflammatory disorders, fibrotic diseases, and oncology. In oncology, the interaction between PTX3 and FGF2 serves as a regulatory checkpoint for angiogenesis, prompting the development of both PTX3-derived peptide mimetics (to block FGF2-driven tumor growth) and monoclonal antibodies targeting PTX3 where it acts as a pro-tumorigenic driver. As these diverse therapeutic modalities advance, characterizing target affinity, structural integrity, and ligand-binding kinetics remains paramount.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Academic Institutes, Biotech Startups | Inflammatory Diseases, Oncology | Affinity & Epitope Mapping (Need native glycosylated PTX3) |
| Peptide Mimetics / Small Mol | Oncology-focused Biopharma | FGF2-driven Solid Tumors | Inhibition Bioassays (Need functional PTX3-FGF2 binding pairs) |
| Recombinant Proteins | Cardiovascular & Immunology R&D | Ischemia-Reperfusion Injury | Complement Activation Assays (Need high-purity C1q and PTX3) |